AR099563A1 - PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE - Google Patents

PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE

Info

Publication number
AR099563A1
AR099563A1 ARP150100549A ARP150100549A AR099563A1 AR 099563 A1 AR099563 A1 AR 099563A1 AR P150100549 A ARP150100549 A AR P150100549A AR P150100549 A ARP150100549 A AR P150100549A AR 099563 A1 AR099563 A1 AR 099563A1
Authority
AR
Argentina
Prior art keywords
peptides
dengue virus
fork
properties against
antiviral properties
Prior art date
Application number
ARP150100549A
Other languages
English (en)
Inventor
Chinea Santiago Glay
Huerta Galindo Vivian
Elisa Garay Prez Hilda
Falcn Cama Viviana
Miguel Martn Dunn Alejandro
Reyes Acosta Osvaldo
Gonzlez Blanco Sonia
Guirola Cruz Osmany
Sarra Nez Mnica
Pupo Gmez Dianne
Yero Daz Alexis
Jess Mrquez Perera Gabriel
Garateix Surez Rocio
Alvarez Prez Karen
Vzquez Castillo Mariela
Javier Gonzlez Lpez Luis
Original Assignee
Centro De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Ingeniería Genética Y Biotecnología filed Critical Centro De Ingeniería Genética Y Biotecnología
Publication of AR099563A1 publication Critical patent/AR099563A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente está relacionada con péptidos sintéticos estructuralmente constreñidos, que han sido optimizados para la formación de estructura horquilla beta. Dichos péptidos son capaces de inhibir o atenuar la infección por el virus Dengue (DENV). Incluye también composiciones farmacéuticas que contienen estos péptidos sintéticos, las que son útiles para la prevención y/o el tratamiento de las infecciones causadas por DENV. De igual forma, provee un método de tratamiento de las infecciones causadas por este virus.
ARP150100549A 2014-03-03 2015-02-24 PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE AR099563A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2014000026A CU20140026A7 (es) 2014-03-03 2014-03-03 Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Publications (1)

Publication Number Publication Date
AR099563A1 true AR099563A1 (es) 2016-08-03

Family

ID=53008223

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100549A AR099563A1 (es) 2014-03-03 2015-02-24 PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE

Country Status (14)

Country Link
US (1) US9896482B2 (es)
EP (1) EP3115056B1 (es)
JP (1) JP6854644B2 (es)
KR (1) KR102325400B1 (es)
CN (1) CN106132981B (es)
AR (1) AR099563A1 (es)
AU (1) AU2015226580B2 (es)
CA (1) CA2940078C (es)
CU (1) CU20140026A7 (es)
ES (1) ES2733648T3 (es)
MX (1) MX363745B (es)
MY (1) MY181033A (es)
PH (1) PH12016501715B1 (es)
WO (1) WO2015131858A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019523633A (ja) 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23632A1 (es) * 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
CU23630A1 (es) * 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Also Published As

Publication number Publication date
CU20140026A7 (es) 2015-11-27
MX363745B (es) 2019-04-01
EP3115056A2 (en) 2017-01-11
CN106132981B (zh) 2019-11-12
AU2015226580B2 (en) 2018-11-08
KR20160127097A (ko) 2016-11-02
AU2015226580A1 (en) 2016-09-15
CN106132981A (zh) 2016-11-16
BR112016019672A2 (pt) 2017-10-24
WO2015131858A3 (es) 2015-10-29
JP6854644B2 (ja) 2021-04-07
PH12016501715A1 (en) 2016-12-19
ES2733648T3 (es) 2019-12-02
CA2940078A1 (en) 2015-09-11
CA2940078C (en) 2020-11-17
EP3115056B1 (en) 2019-04-03
JP2017509619A (ja) 2017-04-06
US9896482B2 (en) 2018-02-20
KR102325400B1 (ko) 2021-11-12
US20170152290A1 (en) 2017-06-01
WO2015131858A2 (es) 2015-09-11
MX2016011420A (es) 2016-11-16
MY181033A (en) 2020-12-16
PH12016501715B1 (en) 2016-12-19

Similar Documents

Publication Publication Date Title
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
PH12017500207A1 (en) Indoles for use in influenza virus infection
CR20160123A (es) Inhibidores de polimerasa hcv
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
NZ727392A (en) Methods of preparing substituted nucleotide analogs
MA50264A (fr) Méthodes de traitement des infections de type hépatite b
BR112018069974A2 (pt) compostos de tiazolida para o tratamento de infecções virais
CR20160178A (es) Derivados de desoxinojirimicina y sus métodos de uso
UY36221A (es) Derivados de isoindolinona
CO2020005420A2 (es) Compuestos antibacterianos
ECSP19026702A (es) Compuestos novedosos para el tratamiento de enfermedades parasitarias
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
PE20170185A1 (es) Composiciones farmaceuticas para tratar enfermedades infecciosas
ES2982489T3 (es) Composiciones para el tratamiento de afecciones que utilizan virus adeno-asociados recombinantes autocomplementarios
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12016502000A1 (en) Novel bacteriophage and composition comprising same
AR099563A1 (es) PÉPTIDOS HORQUILLA b CON PROPIEDADES ANTIVIRALES CONTRA EL VIRUS DENGUE
EA201301340A1 (ru) Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний
TH1601005264A (es)